Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study) - 20/06/26
, Ludiane Gauthier 3, Aurélie Schmidt 2, Gaëlle Nachbaur 3, Florence Joly 4, 5Highlights |
• | Annual age-standardized incidence rates of endometrial cancer were stable in the incident and metastatic/recurrent cohorts. |
• | In first line, 45.3% of the incident cohort and 7.4% of the metastatic/recurrent cohort underwent surgery alone. |
• | Chemotherapy was the most frequent second-line treatment in both cohorts (incident [35.2%]; metastatic/recurrent [44.2%]). |
• | Median OS and TTNTD were not reached in the incident cohort, and were 2.3 and 1.1 years in the metastatic/recurrent cohort. |
Summary |
Introduction |
The MOONBEAM retrospective cohort study examined epidemiology, treatment patterns, and outcomes in patients with endometrial cancer (EC) in France.
Methods |
Data were obtained from the National Healthcare Database System ( Système N ational des D onnées de S anté ) from 2016–2021. Patients first hospitalized for EC or with first inscription on the Long-Term Disease list during the study period formed an incident EC cohort. A second cohort comprising patients with initial metastatic and/or recurrent EC was also analyzed. Endpoints included annual incidence and prevalence of EC, baseline characteristics, treatment patterns, overall survival (OS), and time to next treatment or death (TTNTD).
Results |
Of 60,083 patients in the incident EC cohort (median follow-up 2.0 years; median age 70 years), 23,060 met criteria for the initial metastatic and/or recurrent EC cohort (median follow-up 1.2 years; median age 71 years). Sociodemographic characteristics and comorbidities were similar between cohorts. In first line, 45.3% of the incident EC cohort and 7.4% of the metastatic/recurrent cohort underwent surgery alone, while 5.2% and 31.2%, respectively, received chemotherapy. Chemotherapy alone was the most frequent intervention in both cohorts. Median OS and TTNTD from index date were both not reached in the incident EC cohort, and 2.3 and 1.1 years, respectively, in the metastatic/recurrent EC cohort. At 2 years of follow-up, 21% of patients in the incident EC cohort and 37% in the metastatic/recurrent EC cohort had switched to second-line treatment.
Discussion |
The MOONBEAM study highlights the need for improved first-line treatments for metastatic and/or recurrent EC.
Le texte complet de cet article est disponible en PDF.Keywords : Endometrial cancer, Incidence, Prevalence, Survival, Treatment patterns, Real-world study
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?